OCT 06, 2016 10:30 AM PDT

Precision Genomics and Precision Medicine for Immuno-Oncology

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Manager, Field Applications Scientist, Personalis, Inc.
    Biography
      Erin Newburn, MS, PhD, joined Personalis as a Field Application Scientist in 2013 with over 12 years of research experience in the areas of molecular biology, genetics, and biotechnology. As the Field Applications Manager, Erin's team has the responsibility for providing both pre and post-sale technical support for the Personalis ACE Cancer Portfolio. She completed her postdoctoral training at the National Institute of Mental Health (NIMH) investigating candidate susceptibility genes for major psychiatric illnesses. Erin received her Ph.D. from the Ohio State University in Integrated Biomedical Science as a Presidential Fellow.

    Abstract:

    Tumors often evade immune destruction by adapting and circumventing immune checkpoints to create resistance.  This adaptive immunity can be reversed to stimulate the endogenous immune response.  Extensive efforts using Immunotherapeutic approaches are currently being investigated for various cancer types to activate our immune system, making it able to recognize these cancer cells and destroy them.  Due to the rapid expansion of genomic technologies, Precision Medicine in cancer is leading to exciting therapeutic capabilities.  By a deeper understanding of the tumor genetics, patients can be prescribed more effective therapies or even avoid those that may be potentially adverse.  This webinar will highlight the current renaissance in immunotherapy and discuss the expanding role of both genomics and transcriptomics in providing more personalized cancer care.

    Learning Objectives:

    • Review of the opportunities for precision medicine in immuno-oncology from checkpoint modulators to adoptive cell therapy
    • Understanding the key accuracy challenges in utilizing technologies like NGS for the development of particular immunotherapies such as personalized cancer vaccines
    • Evaluation of the current methods to predict the likelihood of positive response to immunotherapy


     


    Show Resources
    You May Also Like
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    JUN 29, 2018 09:00 AM PDT
    C.E. CREDITS
    JUN 29, 2018 09:00 AM PDT
    DATE: June 29, 2018TIME: 09:00AM PDT, 12:00PM EDT There is significant epidemiological evidence to suggest that the consumption of a high-broccoli diet is associated with a r...
    Loading Comments...